Roquefort Therapeutics PLC Investor Presentation
March 21 2022 - 5:34AM
RNS Non-Regulatory
TIDMROQ
Roquefort Therapeutics PLC
21 March 2022
21 March 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Investor Presentation
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech
company focused on early-stage opportunities in the biotechnology
sector, is pleased to announce that Chairman Stephen West and Chief
Scientific Officer Graham Robertson will provide a live
presentation giving an Introduction to the Company via the Investor
Meet Company platform on Friday, 25(th) March 2022 at 9am GMT.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and can
arrange to meet ROQUEFORT THERAPEUTICS via:
https://www.investormeetcompany.com/roquefort-therapeutics-plc/register-investor
Investors who already follow ROQUEFORT THERAPEUTICS PLC on the
Investor Meet Company platform will automatically be invited.
ENDS
Enquiries:
Roquefort Therapeutics plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George
Beale
+44 (0)20 7466
Optiva Securities Limited (Broker) 5000
+44 (0)20 3411
Christian Dennis 1881
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech
company developing products through the pre-clinical phase prior to
partnering or selling to big pharma. The Company is focused on
developing first in class Midkine inhibiting RNA therapeutic drugs
for the treatment of cancer, chronic inflammatory, autoimmune
disorder and COVID-19. Recent progress within mRNA therapeutics has
led to a reduction in drug development timelines and costs,
increasing the chance of early value creation.
Through extensive research resulting in validation through
publication in over 1,000 scientific publications, Roquefort
Therapeutics has identified the potential to exploit the broad
therapeutic potential of Midkine for a number of clinical
indications of significant unmet need. Roquefort Therapeutics holds
the largest global IP portfolio on Midkine. The Midkine blocking
drug development markets have significant global market potential
(in the multi-billion dollars). Roquefort Therapeutics pre-clinical
programme is currently underway with an initial focus on cancer
treatment aiming to improve immunotherapy responses.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUAOKRUAUOURR
(END) Dow Jones Newswires
March 21, 2022 05:34 ET (09:34 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2023 to Jun 2024